Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study Comparing Adalimumab and Mycophenolate Mofetil for Patients with Steroid-Dependent Non-Infectious Uveitis

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a condition called non-infectious uveitis, which is an inflammation of the middle layer of the eye. The study is specifically looking at cases where the inflammation is dependent on steroids, a type of medication often used to reduce inflammation. The trial will compare the effectiveness and safety of two treatments: adalimumab, which is given as an injection, and mycophenolate mofetil, which is taken as a tablet. The purpose of the study is to see which treatment works better for managing this eye condition.

Participants in the study will receive either adalimumab or mycophenolate mofetil over a period of 36 weeks. Adalimumab will be administered as an injection under the skin, starting with a higher dose on the first day, followed by regular doses every two weeks. Mycophenolate mofetil will be taken orally every day. Some participants may also receive a placebo, which looks like the real medication but does not contain any active ingredients. The study will monitor the participants' eye health and any side effects they may experience during this time.

The trial aims to determine how well each treatment can control the inflammation in the eye and reduce the need for steroids. It will also assess the safety of the treatments by tracking any adverse effects. The study will last until 2027, with regular check-ups to evaluate the participants' progress and the effectiveness of the treatments. This research could help improve treatment options for people with non-infectious uveitis who rely on steroids to manage their condition.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial visit and randomization

    Upon joining the study, eligibility criteria are confirmed. This includes a diagnosis of non-infectious uveitis and recent activity of the condition.

    A written informed consent is required before any study-specific procedures.

    Randomization occurs to assign the treatment group: either adalimumab or mycophenolate mofetil.

  2. Step 2

    Treatment initiation

    For those receiving adalimumab, the initial dose is 80 mg on day 0, followed by 40 mg every 14 days from week 1 to week 35, administered as an injectable solution.

    For those receiving mycophenolate mofetil, the dosage is 2 g per day, taken orally for 36 weeks.

  3. Step 3

    Monitoring and assessments

    Regular assessments are conducted to monitor the condition and treatment response. These include evaluations of visual acuity, anterior chamber cell grade, and vitreous haze grade at specified intervals (weeks 4, 8, 12, 16, 20, 24, 30, 36, and 55).

    Central retinal thickness and macular edema are also assessed using optical coherence tomography.

  4. Step 4

    Primary endpoint evaluation

    The primary endpoint is assessed at 36 weeks. Treatment failure is defined by new active lesions, worsening visual acuity, increased anterior chamber cell grade, or inability to discontinue steroids between weeks 13 and 19.

  5. Step 5

    Secondary endpoint evaluation

    Secondary endpoints include time to treatment failure, changes in visual function, and corticosteroid sparing measures, evaluated up to week 55.

    Safety and tolerability are assessed by monitoring adverse events and treatment discontinuation.

  6. Step 6

    Study completion

    The study is estimated to conclude by June 2027, with final assessments and data collection completed by this time.

Who can join the trial?

17 criteria

  • You must provide written, informed consent before any study-specific procedures are done.
  • You must be at least 18 years old.
  • You must have a diagnosis of non-infectious intermediate, posterior, or pan-uveitis in at least one eye. This is a type of eye inflammation that is not caused by an infection.
  • You must have had recent activity of this eye condition in the last 3 months, even if you are taking more than 7mg of oral prednisone daily. Prednisone is a type of steroid medication. Recent activity can include:
    • Active lesions in the back of the eye.
    • Swelling in the central part of the retina, known as macular edema.
    • At least 2+ cells in the front part of the eye, according to specific criteria.
    • At least 2+ haze in the gel-like substance inside the eye, according to specific criteria.
    • You must have a chest X-ray or CT scan within 12 weeks before joining the study, showing no signs of active tuberculosis (TB), infection, or cancer.
    • If you have a positive test for TB exposure, you can still join if:
      • Your chest X-ray shows no active TB disease.
      • You have no symptoms of TB.
      • If you have a latent TB infection and haven't had preventive treatment, you must agree to complete such treatment.
      • If you are a female who can become pregnant, you must have a negative pregnancy test before joining.
      • If you can have children, you must agree to use effective birth control during the study and for a few months after stopping the study medications. This includes using two methods of contraception, such as:
        • Hormonal birth control (pills, patches, or injections).
        • Intrauterine devices (IUDs).
        • Sterilization procedures like tubal occlusion or vasectomy.
        • Condoms or sexual abstinence.
        • You must be affiliated with a social security system.

Who cannot join the trial?

9 criteria

  • Patients with any other eye disease that could affect the study results.
  • Patients who have had a recent eye surgery.
  • Patients with an active infection that could interfere with the study.
  • Patients who are pregnant or breastfeeding.
  • Patients who have a history of severe allergic reactions to the study medication.
  • Patients who are currently participating in another clinical trial.
  • Patients with a history of drug or alcohol abuse.
  • Patients with a serious medical condition that could affect their safety during the study.
  • Patients who are unable to follow the study procedures or attend study visits.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Adalimumab

    is a medication used in this study to treat non-infectious uveitis, which is an inflammation of the middle layer of the eye. It is administered through an injection under the skin. The goal of using adalimumab in this trial is to evaluate its effectiveness in reducing inflammation and dependency on steroids in patients with this eye condition.

  • Mycophenolate mofetil

    is another medication being tested in this study. It is taken orally and is commonly used to suppress the immune system. In this trial, mycophenolate mofetil serves as the standard treatment to manage non-infectious uveitis, aiming to control inflammation and reduce the need for steroid use.

What is already known about the treatment

  • Adalimumab

    This medication is administered subcutaneously, with an initial dose of 80 mg followed by 40 mg every 14 days. It is currently used in clinical trials to assess its effectiveness in treating non-infectious uveitis, a condition characterized by inflammation in the eye. Adalimumab works by blocking a protein called tumor necrosis factor (TNF), which plays a role in inflammatory processes. It is classified as a TNF inhibitor and is being studied for its potential to reduce inflammation and dependency on steroids in patients with uveitis.

  • Mycophenolate Mofetil

    This medication is taken orally at a dose of 2 grams per day. It is part of the standard care for non-infectious uveitis and is being compared to adalimumab in clinical trials. Mycophenolate mofetil works by suppressing the immune system to prevent inflammation. It is classified as an immunosuppressant and is used to manage conditions where the immune system is overactive, such as in uveitis, to reduce the need for steroids.

Investigated diseases

Non-infectious Uveitis – This is an inflammatory condition affecting the middle layer of the eye, known as the uvea. It can be classified into intermediate, posterior, and pan-uveitis based on the location of inflammation within the eye. The disease is characterized by redness, pain, light sensitivity, and vision changes. Over time, it can lead to complications such as cataracts, glaucoma, or retinal damage if not managed properly. The inflammation can cause a decrease in visual acuity and may result in the formation of new lesions in the retina. The condition often requires ongoing monitoring to assess changes in inflammation and visual function.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase ITrial ID2023-505112-38-00Protocol codeAPHP211032Estimated enrolment120 patientsSponsorAssistance Publique Hopitaux De Paris

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.